Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | GCKR | Q14397 | 1/20 | 0.32 |
| ▸ | EBP | Q15125 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359605 | 1.00 | KDM1A (0.35) | KDM1ARCOR1GRM2NOTUMAKR1C3 | |
| SCHEMBL5370709 | 1.00 | KDM1A (0.35) | KDM1ARCOR1GRM2NOTUMAKR1C3 | |
| SCHEMBL5355389 | 0.72 | IDH1 (0.42) | GRM2GSK3AGSK3BARHSD11B1 | |
| SCHEMBL5356806 | 0.72 | IDH1 (0.42) | GRM2GSK3AGSK3BARHSD11B1 | |
| SCHEMBL5513575 | 0.70 | AR (0.40) | KDM1ARCOR1GRM2NOTUMGSK3A | |
| SCHEMBL5509172 | 0.70 | AR (0.40) | KDM1ARCOR1GRM2NOTUMGSK3A | |
| SCHEMBL5509169 | 0.70 | AR (0.40) | KDM1ARCOR1GRM2NOTUMGSK3A | |
| SCHEMBL9892985 | 0.68 | PTGER2 (0.48) | GRM2NOTUMGSK3AGSK3BMAPT | |
| SCHEMBL14509051 | 0.67 | KDM1A (0.37) | KDM1ARCOR1GRM2NOTUMGSK3A | |
| SCHEMBL9892989 | 0.67 | FPR1 (0.44) | NOTUMKCNH2ARMAPTGCKR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562916-A1 | METHODS FOR PREPARING N-ARYLATED OXAZOLIDINONES VIA A COPPER CATALYZED CROSS COUPLING REACTION | Pfizer Products Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040122226-A1 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC | 2004-06-24 | — | — | US | claimed |
| WO-2004039788-A1 | METHODS FOR PREPARING N-ARYLATED OXAZOLIDINONES VIA A COPPER CATALYZED CROSS COUPLING REACTION | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | claimed |
| US-7223870-B2 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223870-B2 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223870-B2 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070049759-A1 | Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling | PFIZER INC | 2007-03-01 | — | — | US | disclosed |
| US-20070049759-A1 | Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling | PFIZER INC | 2007-03-01 | — | — | US | disclosed |
| US-20070049759-A1 | Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling | PFIZER INC | 2007-03-01 | — | — | US | disclosed |
| EP-1562916-A1 | METHODS FOR PREPARING N-ARYLATED OXAZOLIDINONES VIA A COPPER CATALYZED CROSS COUPLING REACTION | Pfizer Products Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040122226-A1 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
| WO-2004039788-A1 | METHODS FOR PREPARING N-ARYLATED OXAZOLIDINONES VIA A COPPER CATALYZED CROSS COUPLING REACTION | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049759-A1 | Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling | AOC2, SOD1, AOC3 | KDM1A 1977/4885RCOR1 4511/4885GRM2 1750/4885 |
| US-20040122226-A1 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | AOC2, SOD1, AOC3 | KDM1A 2400/4885RCOR1 4514/4885GRM2 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.